S8A) with the net effect of, consistent with prior reports of HDAC inhibition–induced ROS in cancer cells (52–56), increasing total cellular ROS and mitochondrial ROS in PC9 persister cells (Fig. 4, G and H, and fig. Here, HDAC9 is linked to cancer.